All In Biotech

Drug Trial Radar · NCT05283330

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Dec 22, 2022

Primary completion

Jan 2027

Study completion May 2032

Sponsor

Lead sponsor
Orano Med Theranostics, SASIndustry
Sponsor type
Industry
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Conditions

  • Cervical Cancer
  • Breast Cancer
  • Colon Cancer
  • NSCLC
  • mCRPC (Metastatic Castration-resistant Prostate Cancer)
  • Glioblastoma
  • Nonsmall Cell Lung Cancer

Interventions

  • ²¹²Pb-DOTAM-GRPR1Drug

    ²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the Recommended Phase 2 Dose (RP2D) of ²¹²Pb-DOTAM-GRPR1Time frame: 14 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Northwestern University Robert H Lurie Medical Research

    Chicago, Illinois

  • University of Iowa Health Care

    Iowa City, Iowa

  • UK Markey Cancer Center

    Lexington, Kentucky

  • Advanced Molecular Imaging and Therapy

    Glen Burnie, Maryland

  • United Theranostics - Chesapeake

    Glen Burnie, Maryland

  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy)

    Omaha, Nebraska

  • XCancer Omaha / Urology Cancer Center

    Omaha, Nebraska

  • University of Pittsburg Medical Center (UPCM)

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.